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The World Health Organization has selected Malawi as one of three sites to pilot the roll-out of  
RTS,S/AS01 in phase 4 trials. As policy discussions for the expanded use of RTS,S/AS01 continue, it 
will be critical to determine the performance of the vaccine according to seasonal patterns of malaria 
transmission in regions of Africa. Given waning vaccine efficacy over time, this secondary analysis 
demonstrates that administering the vaccine to children in the months prior to malaria season could 
maximize impact of the vaccine. We followed children (5–17 months) and infants (6–12 weeks) assigned 
to one of three groups: (1) vaccine with four doses; (2) vaccine with three doses; (3) control. The primary 
endpoint was defined as episodes of clinical malaria. During the 4-years of follow-up, 658 of 1544 
(42.6%) children and infants had at least one episode of clinical malaria. With each 1-inch increase in 
rainfall per month there was an associated increase in the rate of malaria by 12.6% (95% CI 9.6%, 15.6%, 
P < 0.0001) among children and 15.9% (95% CI 12.8%, 18.9%, P < 0.0001) among infants. There was no 
evidence of effect modification of vaccine efficacy by precipitation (89% power).
Globally, malaria incidence among at-risk populations fell by 37% between 2000 and 2015, with a corresponding 
65% reduction in malaria deaths among children under 5 years of age1. Despite substantial financial and devel-
opmental resources directed toward the reduction of malaria incidence in Africa, Malawi has not seen a signif-
icant decrease in malaria transmission. The entomological inoculation rate (EIR) in Malawi varies depending 
on the method of sampling and calculation, but previous researchers have estimated a weighted median (25–75 
percentile) EIR of 9.1 (1.7, 61.0). This value is similar to Ghana’s weighted median EIR of 7.6 (1.7, 50.4) but is 
much higher than Kenya’s EIR of 0.2 (0.0, 1.1)2. With regard to long-lasting insecticidal-treated nets (LLINs), 
Malawi has seen an increase in the percentage of households with at least one LLIN from 27% in 2002 to 58% 
in 2012, with over 18 million LLINs distributed in the decade. Still, this rate is far below the Global Fund’s tar-
get of 80% of households with at least one LLIN3. Though Malawi’s population is at mesoendemic transmis-
sion risk for malaria4, it was one of only two (out of 44) malaria-endemic countries that saw an increase in a 
population-adjusted Plasmodium falciparum parasite rate among children aged 2–10 years5.
The multi-site, phase 3 trial of RTS,S/AS01, which is the most advanced candidate malaria vaccine, is com-
plete. Across 11 study sites in seven countries in Africa, administration of the vaccine in four doses was shown to 
reduce clinical malaria by 36.3% (95% confidence interval [CI] 31.8%, 40.5%) in children 5–17 months old and 
by 25.9% (95% CI 19.9%, 31.5%) in infants 6–12 weeks old, although efficacy varied across sites6. The European 
Medicines Agency has adopted a positive scientific opinion of the vaccine, leading to a recommendation by 
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the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) and the Malaria Policy Advisory 
Committee (MPAC) for the implementation of large-scale pilot projects1.
In April 2017, the WHO announced that Ghana, Kenya, and Malawi had been selected to participate in the 
Malaria Vaccine Implementation Program (MVIP) of RTS,S/AS01 beginning in 2018. The three countries were 
chosen for their high coverage of LLINs, a high malaria burden even after LLIN scale-up, promising malaria and 
immunization programs, and participation in the Phase 3 trial of RTS,S/AS017. The expected four-year program 
will provide insights on the feasibility of delivering the vaccine in real-life settings, safety in the context of routine 
use, and impact on childhood survival rates. Results from the MVIP will be useful before full-scale deployment 
across the continent. To inform these policy discussions, it will be critical to understand the variation in vaccine 
efficacy over space and time and within different environmental contexts. It is widely understood that RTS,S/
AS01 will not serve as a panacea and that the vaccine must be used in conjunction with other control measures, 
such as LLINs and prompt and appropriate artemisinin combination therapies. However, implementation of the 
vaccine may be particularly effective in certain environments, such as areas where malaria transmission is high 
or seasonal8.
Site-specific data that considers the seasonality of vaccine efficacy have been limited. Apart from other pro-
grammatic considerations, an understanding of the seasonality of transmission and temporal variations in each 
pilot location is critical in deploying effective pilot interventions. For example, seasonal malaria chemopre-
vention is optimally targeted at regions with shorter, more intense malaria transmission seasons and requires 
accurate timing within that season9. Mathematical models have also shown that while absolute vaccine impact 
would increase with increasing levels of malaria transmission, a higher proportion of averted episodes and high 
cost-effectiveness may be possible in lower transmission regions10. Precipitation is particularly interesting because 
greater exposure to infected mosquito bites during the peak rainy season may overwhelm vaccine efficacy. We 
undertook an analysis of the phase 3 trial of RTS,S/AS01 in Lilongwe, Malawi, to evaluate its efficacy against epi-
sodes of clinical Plasmodium falciparum malaria and its effect modification by seasonal variation in precipitation.
Methods
Study Design and Precipitation Data. The details of the study design have been described previously11–13. 
The primary endpoint was defined as development of clinical malaria (fever ≥37.5 °C and Plasmodium falciparum 
parasitemia density >5,000 parasites per microliter) for both age groups11–13. Participants were followed passively 
but parents or legal representatives were told to seek medical care for participants at specified health settings 
for any illness. Parents or legal representatives of all participants witnessed and provided informed consent at 
enrollment to the study. Non-literate parents indicated consent by giving a thumbprint in place of a signature. 
Precipitation data were obtained from the Chitedze Agricultural Center in Lilongwe, Malawi (−13.97S, 33.63E, 
3770 ft). The trial protocol was approved by both the institutional review board (IRB) at UNC Chapel Hill and by 
the Malawi National Health Sciences Research Committee.
Randomization and Masking. From June 2009 until January 2011, children aged 5–17 months and infants 
aged 6–12 weeks were recruited in Lilongwe and randomly assigned (1:1:1) by block randomization to one of 
three groups: (1) a group that received 3 doses of RTS,S/AS01 and a fourth dose 18 months after the third dose 
(V + 1 group); (2) a group that received the same schedule with a control as fourth dose (V group); (3) a group 
that received a rabies vaccine (VeroRab, Sanofi-Pasteur) for children 5–17 months of age and a meningococcal 
serogroup C conjugate vaccine (Menjugate, Novartis) for infants 6–12 weeks of age (C group).
Procedures. Malaria treatment during the study was done in accordance with Malawi national guidelines 
and cases were detected by passive surveillance. The Lilongwe vaccine trial catchment area was identified using 
neighborhood location information from patients who came to the Area 18 Health Center in the previous year. 
Three different geographic data sources were examined to identify the catchment area. To recruit participants, 
community-based information sessions were conducted for families with infants and children who met the 
enrollment age criteria. Flyers were also distributed in the identified communities.
Statistical Analysis. Analyses of vaccine efficacy against clinical malaria were explored in an 
intention-to-treat cohort and included all episodes from the time of enrolment until the date on which the last 
enrolled infant or child completed follow-up.
Vaccine efficacy was defined as the percent reduction in the incidence or hazard rate. Cox proportional-hazards 
models were used to compare rates of first or only malaria episodes between groups14. Monthly precipitation 
was considered in the proportional-hazards model as a time-varying covariate with a time lag of two months. 
Interaction terms for vaccination status and precipitation were included to assess effect modification. Cumulative 
risk of malaria was estimated using the Kaplan-Meier method, and log-rank tests were conducted to compare 
malaria incidence between randomized groups.
Vaccine efficacy against multiple malaria episodes was estimated using negative binomial regression and three 
extensions of the Cox regression model for recurrent events – the Andersen-Gill (AG), the Prentice Williams 
Peterson total time (PWP-TT), and the Prentice Williams Peterson gap time (PWP-GT) models15. In the negative 
binomial regression model, the logarithm of follow-up time was used as an offset. Waning of vaccine efficacy 
was assessed in the negative binomial regression by examining efficacy in years one through four of the study 
follow-up period. The AG model considers time at-risk since study enrolment, assumes a common baseline haz-
ard function for all episodes, and includes a single parameter for the vaccine effect16. The PWP models are strat-
ified proportional hazards models where all children and infants are included in the first stratum, children and 
infants with at least one malaria episode are included in the second stratum, and so forth. The PWP-TT model 
considers time at-risk since study enrolment, whereas the PWP-GT model resets the time index to zero after 
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each malaria episode16. PWP models that allow for vaccine effects to vary across malaria episodes were used to 
estimate vaccine efficacy in each malaria episode (Supplementary Tables 2, 3). The AG, PWP-TT, and PWP-GT 
model estimates of vaccine efficacy against multiple malaria episodes were adjusted for monthly precipitation, 
and interaction terms for vaccination status and precipitation were included to assess effect modification. Events 
occurring within 14 days following a malaria episode that met the primary case definition were excluded to avoid 
counting the same episode twice17. Data were censored at the end of the follow-up period for each participant or 
at the date of emigration, withdrawal of consent, or death. Data were analyzed using SAS software, version 9.4.
Power to detect effect modification of vaccine efficacy by precipitation was assessed by a simulation study. R 
software, version 3.3, was used to conduct the power calculation.
Ethical Statement. The study protocol was approved by the UNC Institutional Review Board and the 
GlaxoSmithKline Investigational Site at Lilongwe, Malawi. The trial was overseen by a Data Safety Monitoring 
Board operating under a charter assisted by a Local Safety Monitor. The study was registered with ClinicalTrials.
gov, number NCT00866619. The study was first received on March 19, 2009 and last updated on April 24, 2017.
Data Availability. The data that supports the findings of this study are available from GlaxoSmithKline but 
restrictions apply to the availability of these data, which were used under license for the current study, and so are 
not publicly available. Data are however available from the authors upon reasonable request and with permission 
of GlaxoSmithKline.
Results
Study Participants. A total of 1986 participants were screened. Of the 1055 children who were screened, 
220 did not meet eligibility criteria, 8 withdrew consent, 9 migrated, and 18 were lost to follow-up; 800 children 
received the first dose of treatment. Of the 931 infants who were screened, 92 did not meet eligibility criteria, 
4 withdrew consent, 7 migrated, and 2 were lost to follow-up; 826 infants received the first dose of treatment. A 
total of 1544 participants in Lilongwe were in the intention-to-treat cohort and had surveillance data available 
after the third dose. Among the 760 children, 247 were randomly assigned to the V + 1 group, 263 to the V group, 
and 250 to the C group. Among the 784 infants, 255 were randomly assigned to the V + 1 group, 257 to the V 
group, and 272 to the C group.
LLIN household use. LLIN household use among study participants was higher than in the general popula-
tion, with LLIN household use among children at 87.8% in the V + 1 group, 82.6% in the V group, and 85.4% in 
the C group at study month 31. Among infants, LLIN household use was 90.4% in the V + 1 group, 87.1% in the 
V group, and 90.9% in the C group (Table 1). The pilot study will be important to assess whether the vaccine can 
be effectively deployed in real-life settings where LLIN usage rates are lower. Baseline characteristics were similar 
between the treatment groups within each age group (Table 1).
Efficacy against the first or only malaria episode. Overall 658 of 1544 (42.6%) children and infants had 
at least one episode of clinical malaria. Among children, 299 of 760 (39.3%) developed malaria: 81 of 247 (32.8%) 
in the V + 1 group, 95 of 263 (36.1%) in the V group, 123 of 250 (49.2%) in the C group. Among infants, 359 of 
784 (45.8%) developed malaria: 102 of 255 (40.0%) in the V + 1 group, 112 of 257 (43.6%) in the V group, 145 of 
272 (53.3%) in the C group (Table 2). The incidence of first malaria episode was significantly different between 
treatment arms for children (log-rank test P = 0.0002) and for infants (log-rank test P = 0.01) (Fig. 1a,b). Among 
children, estimated vaccine efficacies were 41.4% (95% confidence interval (CI) 22.4%, 55.8%, P = 0.0002) for 
the V + 1 group and 33.8% (95% CI 13.4%, 49.3%, P = 0.003) for the V group. Among infants, estimated vaccine 
efficacies were 31.2% (95% CI 11.3%, 46.6%, P = 0.004) for the V + 1 group and 23.3% (95% CI 2.8%, 40.0%, 
P = 0.03) for the V group (Table 2).
Precipitation in the rainy season (November through April) averaged 5.4 inches per month from 2009 through 
2014 with a peak mean of 8.2 inches per month in January. Over each study year, malaria incidence was lowest 
Characteristic
Children Infants
V + 1 
(n = 247)
V 
(n = 263)
C 
(n = 250)
Total 
(n = 760)
V + 1 
(n = 255)
V 
(n = 257)
C 
(n = 272)
Total 
(n = 784)
Follow-up time – mo
 Median 45 45.1 45.5 45.3 33.8 33.9 34.4 34.1
 10th-90th percentile 20.9–49.6 19.3–49.3 21.4–49.0 19.9–49.2 20.8–40.3 20.5–40.1 25.2–40.5 21.8–40.4
Age at first dose*
 Median 12.1 11.6 11.2 11.7 7.8 7.9 8.1 7.9
 10th–90th percentile 6.6–16.5 6.8–16.8 6.5–16.3 6.6–16.5 5.2–11.5 5.3–11.4 5.2–11.4 5.2–11.4
Sex-no. (%)
 Female 124 (50.4) 136 (51.5) 119 (47.6) 379 (49.9) 116 (45.5) 123 (47.9) 137 (50.4) 376 (48.0)
 Male 122 (49.6) 128 (48.5) 131 (52.4) 381 (50.1) 139 (54.5) 134 (52.1) 135 (49.6) 408 (52.0)
LLIN use at month 31 - no. (%) 159 (87.8) 166 (82.6) 158 (85.4) 483 (85.2) 178 (90.4) 175 (87.1) 199 (90.9) 552 (89.5)
Table 1. Demographic characteristics at baseline and follow-up in Malawian children and infants, n = 1544. 
*Ages given in months for children and in weeks for infants.
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during the period from August through October of the dry season (Fig. 2a–d). Precipitation was significantly and 
positively associated with malaria incidence, with each 1-inch increase (decrease) in rainfall per month associated 
with an increase (decrease) in the rate of malaria by 12.6% (95% CI 9.6%, 15.6%, P < 0.0001) among children and 
by 15.9% (95% CI 12.8%, 18.9%, P < 0.0001) among infants, given a time lag of two months. Cox model inter-
action terms between the V + 1 group and precipitation (P = 0.78) and between the V group and precipitation 
(P = 0.85) were non-significant.
Power to detect effect modification. Power to detect effect modification by precipitation was assessed 
by a simulation study. Two thousand data sets were simulated as follows: The sample sizes for infants and children 
allocated to the V + 1 group, V group, and C group matched the sample sizes in the trial. Annual loss to follow-up 
was 15% and maximum follow-up was four years. Incidence of first malaria episode was 0.27 per person-year 
for infants in the C group when precipitation was 2.75 inches per month (the average rainfall for the time period 
under consideration). Vaccine efficacy was 65% when precipitation was less than 2.75 inches per month and vac-
cine efficacy was 25% otherwise. The average number of malaria episodes in the 2,000 simulated data sets was 654 
(similar to the 658 total number of first or only episodes of malaria in the actual data). Effect modification was 
assessed for each data set by fitting a Cox model and testing for an interaction between vaccination and precipita-
tion. The empirical power to detect effect modification was 89%.
Efficacy against all episodes. Multiple malaria episodes were common. From study initiation until study 
end, there were 143 episodes of clinical malaria that met the primary case definition in children in the V + 1 
group, 219 episodes in the V group, and 300 episodes in the C group. In the infant group, there were 263 episodes 
in the V + 1 group, 304 episodes in the V group, and 420 episodes in the C group (Table 2, Fig. 3).
Survival analysis of all malaria episodes by different methods yielded similar results, although the PWP mod-
els with common effects showed lower efficacy estimates compared to the negative binomial and Andersen-Gil 
models. In the negative binomial regression, among children, vaccine efficacies against multiple episodes were 
50.7% (95% CI 32.6%, 64.0%, P < 0.0001) in the V + 1 group and 29.0% (95% CI 4.7%, 47.1%, P = 0.02) in the 
V group compared to the C group. Among infants, vaccine efficacies against multiple episodes were 31.2% (95% 
CI 8.1%, 48.5%, P = 0.01) in the V + 1 group and 20.9% (95% CI 4.0%, 34.9%, P = 0.02) in the V group. By the 
Andersen-Gill model, among children, efficacies against multiple episodes were 49.7% (95% CI 31.6%, 63.5%, 
P < 0.0001) in the V + 1 group and 29.1% (95% CI 3.8%, 47.7%, P = 0.03) in the V group compared to the C 
group. Among infants, vaccine efficacies against multiple episodes were 31.1% (95% CI 8.0%, 48.3%, P = 0.01) in 
V + 1 Group V Group C group
No. of 
individuals
No. of 
events PYAR*
Event 
rate VE (95% CI)
No. of 
individuals
No. of 
events PYAR*
Event 
rate VE (95% CI)
No. of 
individuals
No. of 
events PYAR*
Event 
rate
Children
 First episode 247 81 658.1 0.12 41.4 (22.4, 55.8) 263 95 681.6 0.14 33.8 (13.4, 49.3) 250 123 587.3 0.21
  All episodes 
(NB)** 247 143 811.4 0.18 50.7 (32.6, 64.0) 263 219 853.4 0.26 29.0 (4.7, 47.1) 250 300 839.9 0.36
Infants
 First episode 255 102 540.8 0.19 31.2 (11.3, 46.6) 257 112 536.1 0.21 23.3 (2.8, 40.0) 272 145 537.5 0.27
  All episodes 
(NB)** 255 263 681.7 0.39 31.2 (8.1, 48.5) 257 304 690.2 0.44 20.9 (4.0, 34.9) 272 420 754 0.56
Table 2. Event rates and efficacy of RTS,S/AS01 vaccine against episodes of Plasmodium falciparum clinical 
malaria. *PYAR: person-years at risk. **NB: Negative binomial regression.
Figure 1. Kaplan-Meier estimates of cumulative risk of first malaria episode among children, n = 760 (left) and 
infants, n = 784 (right). Y-axis measures the cumulative risk of first malaria episode. Values at each ten-month 
interval are the number of children or infants remaining at risk.
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Figure 2. Seasonal precipitation and malaria incidence among children in Lilongwe, Malawi, n = 760 (top left), 
of treatment groups among children (bottom left), among infants, n = 784 (top right), and of treatment groups 
among infants (bottom right). Rate of malaria is measured as episodes per person-year (p-y). Note that infants 
had not yet been enrolled in the trial following the first seasonal rainfall peak in 2010.
Figure 3. Distribution of malaria episodes among treatment and age groups. SD: Standard deviation.
www.nature.com/scientificreports/
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the V + 1 group and 27.5% (95% CI 2.6%, 46.1%, P = 0.03) in the V group. By the PWP-TT model with common 
effects, among children, efficacies against multiple episodes were 33.1% (95% CI 21.2%, 46.0%, P = 0.0002) in 
the V + 1 group and 14.3% (95% CI 1–3.5%, 29.1%, P = 0.11) in the V group. Among infants, vaccine efficacies 
against multiple episodes were 13.9% (95% CI −1.5%, 26.9%, P = 0.07) in the V + 1 group and 8.4% (95% CI 
−7.5%, 22.0%, P = 0.28) in the V group. By the PWP-GT model with common effects, among children, efficacies 
against multiple episodes were 36.2% (95% CI 21.1%, 48.4%, P < 0.0001) in the V + 1 group and 17.1% (95% CI 
0.2%, 31.1%, P = 0.04) in the V group. Among infants, efficacies against multiple episodes were 17.0% (95% CI 
2.5%, 29.4%, P = 0.02) in the V + 1 group and 11.8% (95% CI −3.2%, 24.7%, P = 0.12) in the V group (Table 3).
There was no evidence that vaccine efficacy in children changed during the rainy season, as indicated by the 
non-significant interaction between treatment group and precipitation in the AG model (P = 0.38 in the V + 1 
group; P = 0.73 in the V group), PWP-TT model (P = 0.36 for the V + 1 group; P = 0.59 in the V group), and 
PWP-GT model (P = 0.47 in the V + 1 group; P = 0.88 in the V group). Neither did vaccine efficacy change for 
infants during the rainy season, as indicated by the non-significant interaction between treatment group and 
precipitation in the AG model (P = 0.71 in the V + 1 group; P = 0.51 in the V group), PWP-TT model (P = 0.69 
for the V + 1 group; P = 0.28 in the V group), and PWP-GT model (P = 0.75 in the V + 1 group; P = 0.37 in the 
V group).
Waning in Vaccine Efficacy. Waning of vaccine efficacy was assessed by estimating efficacy separately for 
each year of study follow-up. Among children, vaccine efficacy was 70.1% (95% CI 50.8%, 81.8%, P < 0.0001) in 
the V + 1 group and 55.1% (95% CI 31.6%, 70.4%, P = 0.0002 in the V group in the first year. By the third year 
children who received RTS,S/AS01 as the booster dose (V + 1 group) were still protected with a vaccine efficacy of 
42.1% (95% CI 8.6%, 63.3%, P = 0.02), but those who did not (V group) were no longer protected, with a vaccine 
efficacy of 25.9% (95% CI −12.5%, 51.1%, P = 0.16). Among infants, vaccine efficacy declined from 63.0% (95% 
CI 44.3%, 75.4%, P < 0.0001) in the V + 1 group and 41.2% (95% CI 16.8%, 58.5%, P = 0.003) in the first year to 
17.5% (95% CI −88.1%, 63.8%, P = 0.65) in the V + 1 group and 11.0% (95% CI −98.7%, 60.1%, P = 0.78) in the 
V group in the fourth year. By the third year, as in the case of children, infants in the V + 1 group were protected, 
with a vaccine efficacy of 37.0% (95% CI 9.7%, 56.1%, P = 0.01) while infants in the V group were no longer pro-
tected, with a vaccine efficacy of 8.5% (95% CI −26.1%, 33.6%, P = 0.59) (Supplementary Table 1).
Discussion
While precipitation was associated with the incidence of clinical malaria in a seasonal malaria setting in Malawi, 
the efficacy of RTS,S/AS01 vaccine was not modified by variations in precipitation patterns. This information will 
be valuable for roll-out strategies for RTS,S/AS01, particularly in areas with transmission patterns where seasonal 
malaria chemoprevention is effective. The majority of this burden lies in the Sahel sub-region and a band across 
sub-Saharan Africa that includes most of Namibia, Zambia, Malawi, and Mozambique, where a combined 39 mil-
lion children under five are at-risk for malaria17. Pilot programs will soon be underway to assess whether routine 
immunization can deliver the four-dose schedule effectively, whether the vaccine can prevent deaths, and to what 
extent the safety concerns identified in phase 3 trials are confirmed in larger phase 4 trials18. However, for these 
pilot programs to be successful, they must be implemented in a way that recognizes differences in vaccine per-
formance across a variety of transmission intensity regions. Considering waning vaccine efficacy over time, this 
study demonstrates that among seasonal transmission regions, implementation of the vaccine should be given 
differential weighting based on precipitation patterns and its initiation prior to the peak transmission season may 
maximize impact.
Precipitation was significantly associated with increased malaria incidence after a time lag of two months. This 
finding suggests that there is a strong, direct association between rainfall and malaria incidence. The intensity 
of transmission is dependent on the density, biting, and survival rates of the mosquito vector, which are heav-
ily influenced by seasonal temperature and precipitation patterns18. A previous study of malaria attack rates in 
Northern Ghana showed that the risk of infection was lowest during the period of 2–3 months at the end of the 
dry season19. Our model showed that the level of rainfall most strongly predicted malaria incidence after a time 
lag of two months (60.5 days). This time lag is consistent with previous time series analyses in a holo-endemic 
area of Ghana and across the East African highlands, which showed that high-resolution precipitation data could 
directly predict malaria incidence among children less than 15 years of age20, 21. This period of time also closely 
Model*
Children Infants
V + 1 versus C 
(95% CI) p-value
V versus C 
(95% CI) p-value
V + 1 versus C 
(95% CI) p-value
V versus C 
(95% CI) p-value
Negative Binomial 50.7%  (32.6%, 64.0%) <0.0001
29.0%  
(4.7%, 47.1%) 0.02
31.2%  
(8.1%, 48.5%) 0.01
20.9%  
(4.0%, 34.9%) 0.01
Andersen-Gill 49.7%  (31.6%, 63.5%) <0.0001
29.1%  
(3.8%, 47.7) 0.03
31.1%  
(8.0%, 48.3%) 0.01
27.5%  
(2.6%, 46.1%) 0.03
PWP Total Time 33.1%  (21.2%, 46.0%) 0.0002
14.3%  
(−3.5%, 29.1%) 0.11
13.9%  
(−1.5%, 26.9%) 0.07
8.4%  
(−7.5%, 22.0%) 0.28
PWP Gap Time 36.2%  (21.1%, 48.4%) <0.0001
17.1%  
(0.2%, 31.1%) 0.04
17.0%  
(2.5%, 29.4%) 0.02
11.8%  
(−3.2%, 24.7%) 0.12
Table 3. Comparison of four models for estimating vaccine efficacy against all clinical malaria episodes. *All 
models except for the negative binomial are adjusted for monthly precipitation.
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matches the theoretical vector-parasite-host cycle, which includes the growth of the Anopheles mosquito from egg 
to reproductive age, the development of the Plasmodium falciparum parasite in the vector from gametocytes to 
sporozoites, and the incubation period in the human host from infection to onset of malaria symptoms22.
Age played an important role in the number of clinical malaria episodes observed, with infants significantly 
more likely to experience multiple episodes of malaria. Consistent with findings from the phase 3 trial, vaccine 
efficacies were higher among children compared to infants in the negative binomial model, AG model, and PWP 
models6. This observed difference may be explained in part by differences in naturally acquired immunity and 
physiological effects between the two age groups23. Due to the lower efficacy rates observed among infants, the 
WHO Strategic Advisory Group of Experts on Immunization and the Malaria Policy Advisory Committee jointly 
decided that it would not recommend RTS,S vaccination among this younger age group24. However, it is likely 
that continued reductions in malaria exposure will lead to an increased burden among children over five-years 
old. In a comparison of four mathematical models, enhanced prevention measures and RTS,S vaccination was 
predicted to cause such an age shift in malaria incidence, disproportionately affecting children of older ages10. 
Pilot implementations should assess the magnitude of the predicted age shift and its impact on severe disease and 
mortality. Future studies would be needed to establish safety and immunogenicity of the vaccine against older age 
groups, including adults.
Extensions of the Cox model for estimating vaccine efficacy against all clinical episodes showed significant 
efficacy for both the V + 1 group and V group. In each instance, the PWP models (total time and gap time) 
indicated lower vaccine efficacies compared to the negative binomial and Andersen-Gill models (Table 3). This 
observed difference may be explained in part by the ability of PWP models to estimate RTS,S efficacy for each 
episode15. The negative binomial model is a reasonable choice for estimating an overall effect in disease reduction 
with time as an offset6, 25, 26, but the added value of the PWP models is the ability to accommodate time-dependent 
variables like precipitation and a more efficient use of data because timing of malaria episodes is considered16. 
The PWP models are especially useful when the effects of covariates such as vaccination and precipitation are 
different in subsequent episodes, which is likely the case because RTS,S efficacy has been shown to wane over 
time6, 16. However, the PWP models also have limitations. For example, the conditional nature of the models leads 
to very small, nonrandom risk sets for later episodes16, making vaccine efficacy estimates for subsequent episodes 
imprecise (95% CIs for hazard ratios in Supplementary Tables 2, 3). In light of these methodological differences, 
it is important that results from extended Cox models are interpreted properly when applied to RTS,S implemen-
tation research.
In conclusion, precipitation was significantly associated with increased malaria incidence among children and 
infants, with a surge in new cases following a time lag of two months. In assessing rates of first malaria episode 
or all malaria episodes, there was no evidence of effect modification of vaccine efficacy by precipitation. These 
findings suggest that despite increased malaria incidence in the rainy season, efficacy of RTS,S/AS01 does not 
change based on time of year. Thus considering waning vaccine efficacy, vaccination prior to peak transmission 
seasons is likely to maximize impact.
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